Swiss pharma company Idorsia (SIX: IDIA) has entered into an exclusive license and supply agreement with EMS SA, Brazil’s largest privately-owned pharmaceutical company, to bring insomnia drug Quviviq (daridorexant) to patients across Latin America. This partnership marks another milestone in Idorsia’s mission to make Quviviq available worldwide.
Dr Srishti Gupta, chief executive Idorsia, commented: “We are very excited to join forces with EMS, a market leader with exceptional commercial reach and expertise. This collaboration is a strategic step forward in our global expansion, ensuring that patients in Latin America will soon have access to our innovative treatment for insomnia – the only medication to have shown improvement on daytime functioning and treat insomnia as a 24-hour disorder. Together, we aim to transform the nights and days for millions of people struggling with this condition.”
Under the licensing and supply agreement, EMS will be responsible for the registration and commercialization of Quviviq in Latin America. The filing of a regulatory dossier with medicines regulator ANVISA to obtain marketing authorization in Brazil took place in 2025. Idorsia is entitled to receive: total milestone compensation of $20 million for the execution of the agreement, first filing and launch of Quviviq; Supply price plus double-digit royalties on net sales in Brazil and Mexico; Shared milestone payments due to EMS and royalties by sub-licensees in other Latin America countries.
